European Industry Played Key Role In Mitigating COVID-19
Detailed Modelling And Industry Co-ordination Were Central To Managing Pandemic
In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.
You may also be interested in...
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.